GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eidos Therapeutics Inc (NAS:EIDX) » Definitions » Price-to-Owner-Earnings

Eidos Therapeutics (Eidos Therapeutics) Price-to-Owner-Earnings : (As of May. 13, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Eidos Therapeutics Price-to-Owner-Earnings?

As of today (2024-05-13), Eidos Therapeutics's share price is $122.21. Eidos Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Eidos Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


EIDX's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 35.03
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-13), Eidos Therapeutics's share price is $122.21. Eidos Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2020 was $-2.65. Therefore, Eidos Therapeutics's PE Ratio for today is At Loss.

As of today (2024-05-13), Eidos Therapeutics's share price is $122.21. Eidos Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-2.65. Therefore, Eidos Therapeutics's PE Ratio without NRI for today is At Loss.


Eidos Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Eidos Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eidos Therapeutics Price-to-Owner-Earnings Chart

Eidos Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19
Price-to-Owner-Earnings
- - - -

Eidos Therapeutics Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Eidos Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Eidos Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eidos Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eidos Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Eidos Therapeutics's Price-to-Owner-Earnings falls into.



Eidos Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Eidos Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=122.21/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eidos Therapeutics  (NAS:EIDX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Eidos Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Eidos Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Eidos Therapeutics (Eidos Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
101 Montgomery Street, Suite 2000, San Francisco, CA, USA, 94104
Eidos Therapeutics Inc is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. TTR is a protein that occurs naturally in the form of a tetramer and performs multiple beneficial roles, including the transport of essential hormones and vitamins. The company's product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR.
Executives
Uma Sinha director, officer: Chief Scientific Officer C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94101
Franco Valle officer: Senior Vice President, Finance 999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070
Cameron Turtle officer: Chief Business Officer C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94104
Jonathan C Fox officer: See Remarks C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Suzanne Sawochka Hooper director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Douglas Rohlen director 3600 HOLLY LANE NORTH, SUITE 40 PLYMOUTH MN 55447
Eric Aguiar director 888 7TH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Rajeev M. Shah director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ali J. Satvat director, 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO., 2800 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
William Lis director PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Christine Siu officer: CFO and Secretary C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94101
Bridgebio Pharma, Inc. 10 percent owner 421 KIPLING STREET PALO ALTO CA 94301
Neil Kumar director, 10 percent owner, officer: Chief Executive Officer C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304
Hoyoung Huh director C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Peter Kolchinsky 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116

Eidos Therapeutics (Eidos Therapeutics) Headlines

From GuruFocus